Drug-Induced Extrapyramidal Symptoms: Types, Clinical Features, and Management
Drug-induced extrapyramidal symptoms (EPS) are categorized into acute reactions (dystonia, parkinsonism, akathisia) and delayed reactions (tardive dyskinesia), with management prioritizing immediate dose reduction or switching to atypical antipsychotics, followed by targeted pharmacologic interventions based on the specific EPS subtype. 1
Types and Clinical Features
Acute Extrapyramidal Symptoms
These typically occur during initial treatment phases, with children and adolescents at higher risk than adults 1, 2:
1. Acute Dystonia
- Presentation: Sudden spastic contraction of distinct muscle groups involving neck, eyes (oculogyric crisis), or torso 1, 2
- Timing: Occurs within 3-5 days after starting antipsychotic or dose increase 3
- Risk factors: Young age, male gender, high-potency agents (e.g., haloperidol) 1
- Critical warning: Laryngospasm can be life-threatening 1, 2
2. Drug-Induced Parkinsonism
- Presentation: Bradykinesia, tremors, and rigidity mimicking idiopathic Parkinson's disease 1, 2
- Timing: Generally appears within first 3 months of treatment 3
- Diagnostic challenge: Difficult to differentiate from negative symptoms of schizophrenia or catatonia 1
3. Akathisia
- Presentation: Severe subjective restlessness with objective motor agitation (pacing, inability to sit still) 1, 2
- Timing: Days to weeks after antipsychotic exposure 3
- Clinical pitfall: Commonly misinterpreted as psychotic agitation or anxiety, leading to inappropriate dose increases 1
- Impact: Major cause of medication noncompliance and difficult to treat 1
Delayed Extrapyramidal Symptoms
4. Tardive Dyskinesia (TD)
- Presentation: Involuntary athetoid or choreic movements, primarily orofacial (tongue movements, grimacing, chewing), but can affect any body part 1
- Timing: Associated with long-term neuroleptic use 1
- Prevalence: Up to 50% of youth receiving neuroleptics may experience some form of tardive or withdrawal dyskinesia 1
- Prognosis: May persist even after medication discontinuation, unlike withdrawal dyskinesias which typically resolve 1
Management Algorithm
Step 1: Initial Assessment and Risk Stratification
For all EPS presentations:
- Confirm drug history, particularly dopamine antagonists (90% of pediatric cases involve antiemetic use, not antipsychotics) 4
- Document baseline abnormal movements before initiating treatment 1
- Monitor every 3-6 months using structured tools like the Abnormal Involuntary Movement Scale 1
Step 2: Acute Dystonia Management
Immediate treatment (life-threatening if laryngeal involvement):
- Anticholinergic medications (first-line) 1, 3
- Antihistaminic medications (alternative) 1
- Benzodiazepines (alternative) 3
Prevention in high-risk patients:
- Consider prophylactic antiparkinsonian agents, especially in young males or those with prior dystonic reactions 1
- Reevaluate need after acute phase; many patients no longer require prophylaxis during long-term therapy 1
Step 3: Drug-Induced Parkinsonism Management
Treatment hierarchy:
- Lower antipsychotic dose if clinically feasible 3
- Add anticholinergic agent 1, 2
- Add mild dopaminergic agent (amantadine) 1
- Switch to low-potency or atypical antipsychotic 3
Critical consideration: Early diagnosis and rapid withdrawal improves possibility of complete recovery 2
Step 4: Akathisia Management
Treatment is challenging and requires stepwise approach:
- First-line: Lower antipsychotic dose if clinically feasible 1
- Second-line: β-blockers (most effective, particularly lipophilic agents like propranolol and metoprolol) 3
- Third-line: Benzodiazepines 1
- Note: Antiparkinsonian agents are NOT consistently helpful 1
Step 5: Tardive Dyskinesia Management
No specific treatment exists other than discontinuation 1:
- If patient in full remission: Continue current dose only if dose change will likely precipitate relapse 1
- Otherwise: Attempt to lower dose or switch to atypical antipsychotic with lower EPS risk 1
- Prevention is paramount: Adequate informed consent, baseline documentation, and regular monitoring 1
Drug Selection Considerations
High-potency typical antipsychotics (haloperidol, fluphenazine) produce more EPS 1, 5
Low-potency typical antipsychotics (thioridazine, chlorpromazine) have more anticholinergic effects but fewer EPS 1
Atypical antipsychotics have diminished risk of EPS and tardive dyskinesia compared to typical agents 5:
- Risperidone: EPS may occur at ≥2 mg/day 5
- Olanzapine and quetiapine: Generally well tolerated 5
- However: Atypical agents have NOT eliminated EPS, particularly when used at higher-than-recommended doses 6
Critical Clinical Pitfalls
Prophylactic antiparkinsonian use: Routine prophylaxis is harmful; only use in high-risk patients and discontinue after 2 weeks if no EPS develops 6
Long-term antiparkinsonian treatment: Not therapeutically beneficial; gradual withdrawal will not produce EPS recurrence 6
Akathisia misdiagnosis: Frequently mistaken for worsening psychosis, leading to inappropriate antipsychotic dose increases 1
Anticholinergic burden: Review total medication regimen; anticholinergics have their own side effects and may worsen cognitive symptoms 7
Metoclopramide in children: Liquid medication overdose is a common cause of EPS in children under 2 years 4
Drug-induced extrapyramidal effects in pregnancy: Phenothiazines and metoclopramide can cause EPS; withdraw drug if symptoms occur 8